Rena Conti

Determining drug value: Let’s start with the evidence

  • October 24, 2019

Last month, I was pleased to speak at the Institute for Health Policy forum that delved into a critical topic in the drug pricing dialogue: drug value. When I arrived in Washington, D.C., I was struck by how far we’ve…

Drug policy 101: Breaking down different types of drug products

  • October 22, 2019

As patients, providers, and health systems continue to grapple with unsustainably high drug prices in the United States, it is important for policymakers to understand the distinct differences between broad categories of therapies as they examine potential solutions.

Drug policy 101: The state of the pharmaceutical evidence base

  • September 26, 2019

Having sound evidence about a drug’s safety and effectiveness is critical to understanding its benefits and value. In recent years, shifts in the pharmaceutical evidence base have created challenges for evaluating drugs after they come to market.

Drug policy 101: Drug patents

  • July 31, 2019

As drug prices continue rising unsustainably in the United States, patients and payers need to understand — and policy makers need to address — how pharmaceutical companies use patents to maintain monopolies and pricing power.

Kaiser Permanente’s 2025 environmental stewardship goals: Progress in Oregon

  • June 26, 2019

As the nation’s largest integrated health system, Kaiser Permanente is committed to a healthy environment through responsible stewardship and sustainability practices.  As climate change accelerates, the risks to human health continue to grow. In 2016, Kaiser Permanente pledged to achieve…